Company Description
Processa Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing the chemotherapy drugs to improve the safety and efficacy of cancer treatment.
Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells.
Its pipeline includes three Chemotherapy drugs, including Capecitabine, PCS6422 and capecitabine to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; Gemcitabine, PCS3117 to treat pancreatic, lung, ovarian, breast, and other cancers; and Irinotecan, PCS11T to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers.
Processa Pharmaceuticals, Inc. was incorporated in 2011 and is based in Hanover, Maryland.
| Country | United States |
| Founded | 2011 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 13 |
| CEO | George K. Ng Esq., J.D. |
Contact Details
Address: 7380 Coca Cola Drive, Suite 106 Hanover, Maryland 21076 United States | |
| Phone | 443-776-3133 |
| Website | processapharmaceuticals.com |
Stock Details
| Ticker Symbol | PCSA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001533743 |
| CUSIP Number | 74275C205 |
| ISIN Number | US74275C3043 |
| Employer ID | 45-1539785 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| George K. Ng Esq., J.D. | Chief Executive Officer |
| Dr. David Young Ph.D., Pharm.D. | Co-Founder, President of Research and Development and Director |
| Dr. Sian E. Bigora Ph.D., Pharm.D. | Co-Founder and Chief Development and Regulatory Officer |
| James H. Stanker | Chief Financial Officer |
| Patrick Lin | Co-Founder, Chief Business and Strategy Officer |
| Wendy J. Guy | Co-Founder, Chief Administrative Officer and Corporate Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 11, 2024 | 8-K | Current Report |
| Apr 4, 2024 | 8-K | Current Report |
| Mar 29, 2024 | 10-K | Annual Report |
| Feb 21, 2024 | 8-K | Current Report |
| Feb 6, 2024 | 8-K | Current Report |
| Jan 30, 2024 | 8-K | Current Report |
| Jan 29, 2024 | 424B4 | Prospectus |
| Jan 26, 2024 | EFFECT | Notice of Effectiveness |
| Jan 25, 2024 | 8-K | Current Report |
| Jan 22, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |